Probiogen
ProBioGen AG is a leading Contract Development and Manufacturing Organization (CDMO) and technology provider specializing in cell line engineering, process development, GMP manufacturing of biopharmaceuticals, viral vectors, vaccines, and proteins. With proprietary technologies and a focus on innovation, they support clients in biopharma and biotech sectors to develop and produce high-quality biologics efficiently and reliably. Their services include cell line development, process optimization, GMP manufacturing, analytical services, technology transfer, and regulatory support, all aimed at advancing tomorrow's medicines and improving patient outcomes.
Industries
Nr. of Employees
large (251-1000)
Probiogen
Herbert-Bayer-Straße 8, 13086 Berlin, Germany
Patents
Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders
US-9765158-B2
View DetailsEnhancement of protein production yield mediated by a fast shuttling CDC42 GTPase
US-9163089-B2
View Details
Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders
US-9765158-B2
View DetailsEnhancement of protein production yield mediated by a fast shuttling CDC42 GTPase
US-9163089-B2
View DetailsProducts
Producer cell line platforms (mammalian and avian hosts)
Optimized suspension-adapted production host cell strains for stable expression of recombinant proteins and for viral vector production; characterized for genetic stability and metabolic performance.
Transposase-mediated integration platform
Gene delivery and stable-integration workflows using targeted transposase/transposon strategies to enable rapid, efficient generation of productive, stable pools and clones.
Glycoengineering methods for Fc modulation
Process and cell-line based strategies to control Fc glycan composition (e.g., afucosylation) to modulate effector functions such as ADCC.
Viral vector production platforms
Platform capabilities for production of lentiviral, AAV, adenoviral and poxvirus vectors including packaging/producer cell-line approaches and transient transfection options for different scales.
Producer cell line platforms (mammalian and avian hosts)
Optimized suspension-adapted production host cell strains for stable expression of recombinant proteins and for viral vector production; characterized for genetic stability and metabolic performance.
Transposase-mediated integration platform
Gene delivery and stable-integration workflows using targeted transposase/transposon strategies to enable rapid, efficient generation of productive, stable pools and clones.
Glycoengineering methods for Fc modulation
Process and cell-line based strategies to control Fc glycan composition (e.g., afucosylation) to modulate effector functions such as ADCC.
Viral vector production platforms
Platform capabilities for production of lentiviral, AAV, adenoviral and poxvirus vectors including packaging/producer cell-line approaches and transient transfection options for different scales.
Services
Stable and suspension-adapted producer cell line development for recombinant proteins and viral vectors with high-throughput cloning, stability testing and integration with analytics and process development.
GMP production of master and working cell banks with in-process analytics and supply of high-density cryo-seed intermediates to accelerate seed-train timelines.
Integrated upstream and downstream process development including fed-batch, perfusion, intensified modes and bespoke purification process design to support scalable manufacturing.
GMP production of clinical-grade drug substance using disposable bioreactors (proteins up to 1000 L; viral vectors up to 200 L), followed by in-house semi-automated aseptic filling and DP manufacturing.
Coordinated tech-transfer services including transfer planning, documentation, training, online support and supervised material shipments to/from other CDMOs or developers.
Method development, qualification and GMP release testing using orthogonal analytical methods; viral-specific panels include ddPCR/qPCR, infectivity assays, capsid/p24 ELISA, RCL testing and NGS-based characterization.
Stable and suspension-adapted producer cell line development for recombinant proteins and viral vectors with high-throughput cloning, stability testing and integration with analytics and process development.
GMP production of master and working cell banks with in-process analytics and supply of high-density cryo-seed intermediates to accelerate seed-train timelines.
Integrated upstream and downstream process development including fed-batch, perfusion, intensified modes and bespoke purification process design to support scalable manufacturing.
GMP production of clinical-grade drug substance using disposable bioreactors (proteins up to 1000 L; viral vectors up to 200 L), followed by in-house semi-automated aseptic filling and DP manufacturing.
Coordinated tech-transfer services including transfer planning, documentation, training, online support and supervised material shipments to/from other CDMOs or developers.
Method development, qualification and GMP release testing using orthogonal analytical methods; viral-specific panels include ddPCR/qPCR, infectivity assays, capsid/p24 ELISA, RCL testing and NGS-based characterization.
Expertise Areas
- Cell line engineering for biologics and viral vectors
- Upstream and downstream process development (proteins and viral vectors)
- Process intensification and perfusion-based manufacturing
- GMP clinical manufacturing and aseptic fill & finish
Key Technologies
- Transposase-mediated stable integration for cell-line generation
- CHO, HEK293 and avian suspension production hosts
- Single-use bioreactor systems (wave, orbital, stirred tank)
- Perfusion technologies and ATF/TFF-integrated workflows